Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
New Delhi: The Delhi High Court has ordered action against the use of oxytocin in dairy colonies in the national capital and directed authorities to take strict action against the use of oxytocin, labelling it as animal cruelty and a criminal offence.
Doctors in the national capital have lauded the recent ruling by the Delhi High Court to crack down on the use of oxytocin in dairy farming, denouncing it as an act of animal cruelty.
Responding to a petition concerning the conditions of dairy farms in Delhi, the High Court directed authorities on Friday to take stringent measures against the use of oxytocin, categorizing it as both animal cruelty and a criminal offence.
Dr Atul Gogia from Ganga Ram Hospital emphasised the health risks associated with consuming dairy products from areas where there is improper disposal of garbage.
He warned of potential contamination leading to various infections, including jaundice and typhoid.
“It’s important to ensure the hygiene of milk products before consumption as there are potential long-term effects of contamination, such as organ damage from heavy metals present in water,” Gogia told PTI videos.
A division bench comprising Acting Chief Justice Manmohan Court has instructed the Delhi government’s Department of Drugs Control to carry out weekly inspections and register cases, which the police will subsequently investigate.
Additionally, the Intelligence Department of Delhi Police has been tasked with identifying the sources of oxytocin production, packaging, and distribution, with orders to take legal action as necessary.
According to a PTI report, “This was a very aware step taken by the High Court because dairies inject cows with a high dose of oxytocin to increase milk production, and then this oxytocin reaches humans through milk and milk products, which is harmful for the human body,” Dr Swati said.
Dr Sanjeev Bagai underscored the importance of the court’s decision, highlighting the considerable medical, social, and environmental risks associated with waste dumps.
He emphasized the potential health threats posed by toxic substances emitted from such sites, including methane and nitrogen compounds, which can lead to severe health ailments such as cancer, respiratory illnesses, cardiovascular diseases, and pregnancy complications.
Powered by WPeMatico
New Delhi- The registration deadline for the National Eligibility cum Entrance Test- Post Graduate (NEET PG) for 2024 is going to end tomorrow i.e. on 6th May 2024 by 11:55 PM, hence interested candidates are advised to apply as soon as possible.
The examination will be conducted on the computer-based platform at various examination centres in 259 cities across the country on June 23, 2024, and the result will be declared by July 15, 2024.
The admit card for NEET PG 2024 is expected to be released on June 18, 2024. Candidates will be informed through SMS/Email alerts and website notices regarding the availability of the admit card on the NBEMS website. Admit cards will not be sent to the candidates by Post/Email, as per the NBE NEET PG 2024 information bulletin.
IMPORTANT DATES
|
S.NO |
PROCESS |
TIMELINES |
|
1 |
Online Submission of Applications |
16th April 2024 (3 PM Onwards) to 6th May 2024 (Till 11:55 PM). |
|
2 |
Edit Window for All Payment Success Applications (Any information/documents can be edited except Name, Nationality, Email, Mobile number and Test City). |
10th May 2024 to 16th May 2024. |
|
3 |
Final and Selective Edit Window to rectify Deficient/Incorrect Images (No further opportunity shall be given) 1Photograph 2 Signatures 3 Thumb Impression |
Pre-Final Edit Window: 28 May to 3rd June 2024 Final Edit Window: 7th June to 10th June 2024. |
|
4 |
Issue of Admit Card. |
18th June 2024. |
|
5 |
Examination Date. |
23rd June 2024. |
|
6 |
Declaration of Result. |
By 15th July 2024. |
|
7 |
The cut-off date for completion of internship towards eligibility for NEET-PG 2024. |
15th August 2024. |
INSTRUCTIONS TO FILL ONLINE NEET PG 2024 APPLICATION FORM
1 New User Registration: All candidates desirous of applying for NEET-PG 2024 shall be required to create an online profile of themselves to generate a UserID and Password.
2 Applicant Login: This User ID and Password so created will allow the candidate to log in as an applicant for the NEET-PG 2024 session and register an online application. The “Go To Application” link will allow the applicant to continue with the application submission immediately after user creation.
3 If the Login password is lost, it can be retrieved by clicking “Forgot Your Password”.
4 Name of Candidate: Please mention your full name as in the Primary Medical Qualification Certificate. The name as entered by the candidate while creating his/her User ID shall be reflected in a non-editable format in his/her examination application form. No change in the name shall be permissible under any circumstances after the submission of an application. The candidate shall be required to produce his/her Government-issued ID proof bearing the same name at the test centre on the test day to seek entry. It is strongly advised not to apply with an error in the candidate’s name as it shall not be allowed to be edited after application submission. If the user has entered his/her name wrongly while registering the user, please create another user with the correct name.
5 Gender and Date of Birth: Indicate your gender and Day, Month & Year of your birth. Please enter the correct date of birth carefully while registering the user.
6 Nationality: Please choose your nationality amongst the options given: Indian, Non-Resident Indian (NRI), Overseas Citizen of India (OCI) and Non-OCI Foreign Nationals. Indian Citizens who are not NRI should choose Indian. An Indian Citizen should choose a Non-Resident Indian if he/she is an NRI. If you are a Foreign National but also an Overseas Citizen of India (OCI), please choose OCI. Foreign Nationals who are not OCI should choose Non OCI Foreign National.
7 Email ID: The email ID chosen by the candidate shall be verified through a system-generated OTP for user creation. The same email ID can not be used for the registration of any other user concurrently. Please note that all email correspondence with the candidate shall be done at this email ID only. Email chosen by the candidate shall be the primary means to communicate with the candidate for examination purposes. Information related to examinations shall be sent at this email ID. Candidates shall also be able to communicate with NBEMS through this registered email only. Correspondence received from any other email ID of the candidate shall not be entertained. Therefore, candidates are advised to choose the email ID carefully. Candidates are required to use the same Email ID for the counselling Registration Form of the designated counselling authority as used in the NBEMS NEET-PG 2024 Application Form.
8 Mobile No: Please provide a unique mobile number for receiving Examination-related communications sent through SMS. The mobile number chosen by the candidate shall NOT be the primary means to communicate with the candidate for examination purposes. The same Mobile No. as used for NBEMS NEET-PG 2024 Registration will be used at the time of Registration for Counseling
9 The UserID/Application ID and password so generated shall be sent to the registered email ID of the candidate for future records.
10 The index page of NEETPG 2024 at NBEMS website https://natboard.edu.in provides a quick link, “Already Registered? To login”. The online application form for NEET-PG 2024 can be accessed through this quick link after the successful creation of the User ID.
11 The candidate can log in using his/her User ID and Password.
12 The application submission process can be completed either in a single sitting or in multiple sittings, as per the candidate’s choice, during the application submission window. However, once an application is successfully completed & submitted, it shall be available for editing certain fields only during the “edit window”.
13 Candidates are advised not to complete & submit their online application in haste to avoid any errors in providing information. Request for making any changes in the date of birth, name, category, nationality or any other information provided in the application shall be summarily rejected. NBEMS does not edit/modify/change any information provided by the candidates in their applications of its own. Candidates have the option to make corrections in any information except name, nationality, test city, mobile number and email ID during the edit window
14 The candidate shall be required to provide information as asked by various heads. It is strongly recommended to keep the required information handy before start applying. Please read the User Manual available on the index page of NEET-PG 2024 for step-wise details asked in the application form.
15 Upload of Prescribed Images (Photograph, Scanned Signatures and Thumb Impression): Please refer to Image Upload Instructions available in the information bulletin in the NBEMS for details of specifications for uploading photographs, signatures and thumb impressions. Images which are not as per prescribed specification shall not be considered and may lead to rejection of the application. Please ensure that the uploaded photograph is a RECENT photograph and in any case, should have not been taken more than 3 months before the date of application submission. Uploading a photograph which is not a recent one or that is not as per prescribed image upload guidelines as detailed in this information bulletin and/or failure to rectify the same in the final edit window shall invite rejection of the application.
16 The test city can be selected from available choices on a first come first serve basis. While the city will be chosen by the candidate himself/herself at the time of online submission of the application form, allotment of the test centre/venue in the chosen city shall be done by NBEMS.
17 After the selection of the test city, the candidate shall be required to pay the prescribed examination fee online. The fee can not be paid through any mode other than the payment gateway available in the online application form.
18 Candidates shall be prompted to preview the entire application before submission to make any corrections if so required. They shall be required to apply after agreeing to the “declaration”. This shall complete the entire process of application submission
19 Acknowledgement of Application Submission: An acknowledgement email shall be sent to the registered email ID confirming the submission of an application by the candidate. Submission of the application shall be completed only after successful payment of the examination fee. Candidate should confirm the status of payment in the application form PDF where ’S’ would stand for “Successful” and “F” would stand for “Failed”.
HOW TO FILL ONLINE NEET PG 2024 APPLICATION FORM
The following sequence shall be observed while filing the online application form:
1 Fill out the user registration form to generate the User ID/Application ID and Password.
2 User ID and Password will be sent through SMS and Email.
3 Complete the application form and upload your Photograph, Scanned signature, Thumb impression & Prescribed documents.
4 Choose your Test City and pay the Examination Fee.
5 Agree to the declaration and Submit the Application.
6 Take a printout of the filled Application form with Transaction ID printed on it and payment status mentioned as “S” (Successful) for records.
EXAMINATION FEE
|
S.NO |
CATEGORIES OF CANDIDATES |
EXAMINATION FEE |
|
1 |
General, OBC and EWS |
Rs. 3500/ |
|
2 |
SC, ST, PWD |
Rs. 2500/- |
The prescribed exam fee should be remitted through a payment gateway provided using a Credit Card or a Debit Card issued by banks in India or other modes as may be made available and have been provided on the web page.
Powered by WPeMatico
Deerfield: Walgreens and Boehringer Ingelheim have announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.
“This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare and research,” the release stated.
Through this collaboration, Boehringer Ingelheim will leverage select Walgreens community pharmacies as clinical trial sites for people living with obesity, overweight and type 2 diabetes. The effort aims to dismantle barriers, improve access, and address equitable health representation in clinical trials, especially among Black and Hispanic adults who are more likely to have obesity in the U.S. and have historically been underrepresented.
“Embracing our pharmacy clinical trial centers in this study underscores our joint commitment to community health and innovation,” said Ramita Tandon, Chief Clinical Trials Officer at Walgreens. “This model not only provides foundational education on clinical research for patients but also empowers individuals, offering them a new pathway to engage in their healthcare through clinical trial participation. It’s a step forward in transforming the landscape of clinical research, helping to make clinical trials more inclusive and accessible.”
Additionally, Boehringer is partnering with EmVenio Research to complement this initiative by introducing mobile research units to extend reach and provide additional options for participation.
“Boehringer is proud to embrace this community-centric approach to clinical research with Walgreens and EmVenio,” said Lennart Jungersten, Senior Vice President, Medicine & Regulatory Affairs at Boehringer Ingelheim U.S. “By bringing clinical trials into the heart of local communities, we’re making them more accessible, helping to provide access to diverse populations with pressing health needs to participate in our clinical trials. Boehringer Ingelheim is committed to helping those living with overweight and obesity to transform lives for generations to come.”
It is estimated that over 1 billion people in the world live with obesity, and numbers are continuing to rise, with an estimated 24% of the entire world population affected by 2035. Obesity is included among cardiovascular, renal and metabolic (C-R-M) diseases, and, collectively, these are the leading cause of death worldwide.
“At EmVenio, we believe that innovation is meaningful and access to clinical trial research should be universal. Our partnership with Boehringer Ingelheim exemplifies our commitment to breaking down barriers and expanding access to transformative healthcare solutions,” says Thad Wolfram, President, EmVenio Research. “By bringing clinical trials directly to local communities, we’re not just conducting research, we’re fostering inclusivity and diversity in clinical trials.”
Leveraging pharmacies and mobile research units for clinical trial research is a forward-thinking approach with the potential to enhance patient outcomes and set a new benchmark for inclusivity. Walgreens will also utilize advanced, real-world insights to identify and engage potential study participants as part of the collaboration.
Powered by WPeMatico
Mumbai: Global pharma major Lupin Limited has announced the launch of Rymti, Lupin’s first biosimilar in Canada, through its partner Sandoz Canada.
Rymti is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents. Rymti is approved for all therapeutic indications of the reference product Enbrel.
Lupin’s Etanercept was first approved for the treatment of rheumatoid arthritis by PMDA in 2019, EMA in 2020, Health Canada in 2022, and since then has offered an effective treatment option for several chronic inflammatory diseases.
Rymti is available as a solution for injection in a pre-filled pen and pre-filled syringe. Data show a high patient acceptance of the easy-to-handle pre-filled pen. Patients favored this latex-free device for self-injection, which can lead to improvement in compliance.
Rymti, with an equivalent efficacy and safety to reference product Enbrel, is an attractive cost-effective treatment alternative that can contribute to sustainable healthcare and treatment options. The etanercept biosimilar Rymti, produced by Lupin, received approval from Canada’s drug regulator, Health Canada (HC), in August 2022, for all indications of the reference product Enbrel.
“We are delighted to announce the launch of Rymti, Lupin’s first biosimilar in Canada through our partner Sandoz,” said Vinita Gupta, Chief Executive Officer, Lupin. “With this important milestone, we continue to advance healthcare accessibility and affordability for patients in Canada.”
“Etanercept is used globally in the fight against a range of severe autoimmune disorders. We are happy to bring etanercept to the patients in Canada. We have diligently worked to build our portfolio to include etanercept ensuring patients have access to effective and affordable equivalent. This launch demonstrates our commitment to fostering healthcare solutions that truly make a difference,” said Dr. Cyrus Karkaria, President Biotechnology, Lupin.
Michel Robidoux, President and General Manager, Sandoz Canada said, “The launch of Rymti is a key milestone for Sandoz Canada. Thanks to our exclusive partnership with Lupin, we’re adding another etanercept option on the Canadian market, increasing access for patients.”
Etanercept is an injectable biologic medicine that inhibits the biological activity of Tumor Necrosis Factor (TNF). TNF is a key cytokine involved in the pro-inflammatory cascade in many chronic, immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis. Etanercept as a soluble TNF receptor fusion protein specifically binds to TNF and blocks its activity, thereby reducing inflammation and disease symptoms.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centres.
Read also: Lupin bags USFDA approval for Loteprednol Etabonate Ophthalmic Suspension
Powered by WPeMatico
Jammu & Kashmir- Jammu and Kashmir (J&K) Board of Professional Entrance Exams has announced the final date of the Common Entrance Test (CET) for admission to B.Sc. Nursing, B.Sc. Paramedical and B.Sc. Technology courses for session 2024 in government and private colleges and institutions of the Union Territory (UT) of Jammu and Kashmir.
On May 26, 2024, the CET exam will be conducted, however, it was earlier tentatively scheduled on May 12, 2024. Meanwhile, information regarding availability, venue and timing of online admit card for the Common Entrance Test will be released separately in due course. However, other terms and conditions will remain the same as mentioned in the earlier notification/notice and e-information brochure, the official notice on this stated.
The CET examination will be conducted offline simultaneously at Jammu and Srinagar centres as may be decided by the Board.
SYLLABUS
The entrance exam is based on the syllabus and curriculum of study of class 12th. It is given as follows along with the overall importance of each topic in the question paper of the entrance examination. The question paper will be based on Physics, Chemistry and Biology subjects with a total marks of 60 per subject.
The earlier notice also stated that the board will not be responsible for any omission or commission in filling out the online application form by the candidate. J&K Board further advised the candidates to remain in touch with the BOPEE website. The Board does not take any responsibility for delays in the publication of notices and notifications in the print media. If so, such publications are not under the control of the Board, notwithstanding the Board notifying it on its official website and forwarding the said notifications/notices etc. for publication in newspapers simultaneously on the date of publication.
To view the notice, click the link below
Powered by WPeMatico
Pune: Granting relief to the resident doctors, who were found involved in the alcohol party incident reported on December 31 last year, the Director of Medical Education and Research (DMER) recently revoked the decision to cancel ‘one academic term’ of these doctors. The action for cancellation of one academic year with expulsion from the hostel for six months was recommended by the college administration after the college authorities conducted an inquiry into the matter.
Although the DMER has revoked the action of one academic term cancellation, the action for expulsion from the hostel for six months with a fine of Rs 300 will continue to remain. Further, the resident doctors have been asked to submit an undertaking assuring that such incidents would not be repeated in the future.
An incident of harassment of female resident doctors was reported last year on December 31, 2023. Back then, some of the PG students at the male residents’ hostel consumed alcohol, went to the resident hostel for the females and created chaos. After the drunk doctors smashed a window of the female hostel resulting in panic, two female residents lodged a complaint to the college administration.
Also Read: BJ Medical College Anaesthesia Medico alleges ragging, probe launched
Reportedly, the Deputy Chief Minister Ajit Pawar has also taken cognizance of the matter and slammed the college and hospital administration for the liquor party and the chaos that took place on the premises on the occasion of New Year’s Eve.
As per the latest media report by Hindustan Times, the incident took place on December 31 and as many as ten resident doctors, nine junior residents and one senior resident doctor, were accused of being involved in the incident who are pursuing MS Orthopaedics and MD courses. Conducting an inquiry into the matter, BJMC had recommended action for one academic year cancellation with expulsion from hostel for six months along with a fine of Rs 300.
Consequently, BJMC sent the proposal to DMER and it was approved by the medical education department on April 19. However, the resident doctors accepted their mistake and approached the DMER requesting to cancel the stern action.
Now the DMER has revoked the cancellation of ‘one academic term’ of these resident doctors involved in the incident. Commenting on the matter, Dr. Dilip Mhaisekar, DMER told HT, “We directed the BJMC dean to revoke the action of one academic term cancellation. However, the action for expulsion from the hostel for six months with a fine of ₹300 will continue to remain. To avoid such incidents in future the resident doctors have been asked to submit an undertaking on a ₹100 stamp paper that such incidents won’t be repeated in the future.”
Dr. Mhaisekar further pointed out that cancellation of one academic term would have long-term effects on the carrier of these doctors. Due to this, the decision was revoked on humanitarian grounds.
Also Read: Ragging at BJ Medical College: Maha DMER seeks Fresh Report from internal panel
Powered by WPeMatico
Karnataka- Through a notice, Rajiv Gandhi University of Health Sciences (RGUHS) has informed about the fee payment and timetable for the conduct of the Super Speciality- DM, MCh exams in June 2024.
The Super Speciality exams are scheduled from 21st June 2024 to 28th June 2024 from 9:00 am to 12 noon.
|
S.NO |
PARTICULARS |
DATE |
|
1 |
Date of Online Filling of Application Forms without fine |
13.05.2024 to 23.05.2024 |
|
2 |
Date of Online Filling Application Forms with fine Rs.100/- |
24.05.2024 to 03.06.2024 |
|
3 |
Date of Online Filling of Application Forms with fine Rs.200/- |
04.06.2024 to 13.06.2024 |
|
4 |
Without fine |
13.05.2024 to 23.05.2024 |
|
5 |
With a fine of Rs.100/- |
24.05.2024 to 03.06.2024 |
|
6 |
With a fine of Rs.200/- |
04.06.2024 to 13.06.2024 |
|
7 |
Last date without fine |
24.05.2024 |
|
8 |
Last date with a fine of Rs.100/- |
04.06.2024 |
|
9 |
Last date with a fine of Rs.200/- |
14.06.2024 |
|
10 |
Last date for submission of filled application forms by the college to the university. |
19.06.2024 |
FEE STRUCTURE
|
S.NO |
PARTICULARS |
AMOUNT |
|
1 |
Examination Application form fee per exam (Including all years) |
Rs.200/- |
|
2 |
Marks Card Fee |
Rs. 300/- |
|
3 |
Examination Fee (Per Paper) |
Rs. 4000/- (Per Paper) |
|
4 |
Provisional Degree Certificate |
PG Degree Rs.750/- |
|
5 |
Convocation Fee a Super Speciality (Indian Nationals) (Foreign National) |
Rs. 6000/- Rs. 6000/- |
TIMETABLE FOR SUPER SPECIALTY EXAMINATION OF JUNE 2024
1 DM NEPHROLOGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
7271 |
|
2 |
24.06.2024 |
MONDAY |
2 |
7272 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
7273 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
7274 |
2 DM CARDIOLOGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9111 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9112 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9113 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9114 |
3 DM ONCOLOGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9121 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9122 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9123 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9124 |
4 DM ENDOCRINOLOGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9191 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9192 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9193 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9194 |
5 DM NEUROLOGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9371 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9372 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9373 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9374 |
6 DM PAEDIATRIC
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9166 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9167 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9168 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9169 |
7 DM PULMONARY MEDICINE
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9116 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9117 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9118 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9119 |
8 DM PAEDIATRIC ONCOLOGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9856 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9857 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9858 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9859 |
9 DM ONCOPATHOLGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9860 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9861 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9862 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9863 |
10 MCh UROLOGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9161 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9162 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9163 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9164 |
11 MCh SURGICAL ONCOLOGY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9131 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9132 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9133 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9134 |
12 MCh PLASTIC SURGERY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9151 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9152 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9153 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9154 |
13 MCh CARIDAC THORACIC SURGERY
|
S.NO |
DATE |
DAY |
PAPER |
QP CODE |
|
1 |
21.06.2024 |
FRIDAY |
1 |
9101 |
|
2 |
24.06.2024 |
MONDAY |
2 |
9102 |
|
3 |
26.06.2024 |
WEDNESDAY |
3 |
9103 |
|
4 |
28.06.2024 |
FRIDAY |
4 |
9104 |
INSTRUCTIONS FOR THE CANDIDATES
1 Candidates are required to pay the convocation fee along with the examination fee.
2 The failed students (repeaters) need not pay the marks card fee.
3 The failed students (repeaters) need not pay the PDC fee and convocation fee as if it has been paid by the students in the earlier examinations. If any revision in the fee structure in respect of Marks card, PDC and convocation fee, then such a difference amount should be paid by the students.
4 The fee once paid cannot be refunded or readjusted under any circumstances.
5 Change of Examination centre is not permitted under any circumstances.
INSTRUCTIONS FOR THE PRINCIPALS/HEADS OF THE INSTITUTIONS
1 The Principals of Colleges are required to furnish attendance of candidates up to the last working day. There is no provision for condonation of shortage of Attendance by the Principal.
2 (A) SC/St and category I candidates are not Exempted from the payment of the examination fee, as per the letter of the Director of Medical Education.
(B) Repeaters belonging to SC/ST/Category —I of all faculties are not exempted from the payment of exam fees. They have to pay the fee like regular students as per the instructions from the Government.
3 Shortage of Attendance: Fee should not be collected from ineligible candidates.
4 Forward the filled-in examination application forms arranged examination-wise / batch-wise / scheme-wise. The statement showing the non-appearance of candidates in any subjects should be sent separately.
5 The filled-in Examination application forms properly signed and affixed with the latest stamp size photographs should reach the Registrar [Evaluation] on or before the specified dates, by Insured Post or Courier.
6 The Principals of colleges should collect the fee from each candidate and send a challan for the consolidated amount in favour of the Registrar (E), draw from any branches of State Bank of Mysore along with the statement showing the details of Names of the candidates, Register Numbers, Subject appearing and fees paid etc., “In triplicate”.
7 The Heads of the Institutions are requested to send the candidates list with Register Numbers and other details of subjects for which they are due to appear in two sets without fail in the format enclosed.
8 The Principals should send separately the statement showing fee details of Provisional Degree Certificate and Convocation Fees collected from the students who are appearing for the first time in the Final Year Examination with details such as Register Number, Name of the Candidate & amount paid through the challan drawn in favour of Registrar (Evaluation), Rajiv Gandhi University Of Health sciences, Bangalore.
Furthermore, Students applying for a Convocation Degree Certificate are instructed to submit the prescribed application form along with a passport-size photo as prescribed. The specifications of the photograph are as follows:
1 Type- JPEG/JPG
2 Size- 33mm X 41mm or 1.3 X 1.6 inches
3 Color- Natural colour so skin tone is clearly visible
4 Recency Taken in the last 6 months
5 Background- Plain white and solid design
6 Smile- No Smile. Only neutral expression
7 Eyes- Open and looking directly at the camera
8 Dimensions and size (pixels)- 10KB to 50KB for pixels: 130 X 160 Minimum and 1000 X 1000 maximum
9 Attire, Clothing dress code- casual or professional preferred.
To view the notice, click the link below
Powered by WPeMatico